Results 71 to 80 of about 2,184,937 (297)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Kinetics of Exciton Emission Patterns and Carrier Transport

, 2009
We report on the measurements of the kinetics of expanding and collapsing rings in the exciton emission pattern. The rings are found to preserve their integrity during expansion and collapse, indicating that the observed kinetics is controlled by charge ...
Butov, L. V., Gossard, A. C., Levitov, L. S., Simons, B. D., Yang, Sen   +4 more
core   +1 more source

KINETICS OF RECOMBINATION PROCESSES [PDF]

, 2002
In order to solve nonlinear kinetic equations for recombination reactions when the production of participating species is driven externally at a time-dependent rate, the authors establish a framework based on the correspondence between these equations ...
RAUH, H, STONEHAM, AM
core   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Holistic approach to dissolution kinetics : linking direction-specific microscopic fluxes, local mass transport effects and global macroscopic rates from gypsum etch pit analysis [PDF]

, 2013
Dissolution processes at single crystal surfaces often involve the initial formation and expansion of localized, characteristic (faceted) etch-pits at defects, in an otherwise comparatively unreactive surface.
Abendan, Alonso-Azcárate, Alonso-Azcárate, Arvidson, Bard, Binnig, Blum, Blum, Bosbach, Bosbach, Bosbach, Brantley, Brown, Buchanan, Burns, Burt, Cama, Cama, Chen, Chow, Chow, Christoffersen, Colombani, Colombani, Compton, Compton, Compton, Dove, Engstrom, Fan, Fleischmann, Ford, Forster, Fujiwara, Gasperino, Hall, Hartman, Heinze, Hong, Howell, Jeschke, Jeschke, Jones, Jones, Jordan, Kowacz, Lasaga, Lasaga, Levich, Liu, Lüttge, Lüttge, Lüttge, MacInnis, Macpherson, Macpherson, Macpherson, Macpherson, Martin A. Edwards, Massimo Peruffo, Mbogoro, McGeouch, McGeouch, Michael M. Mbogoro, Morel, Morse, Nancollas, Olhoeft, Orton, Pachon-Rodriguez, Patrick R. Unwin, Peltonen, Ruiz-Agudo, Ruiz-Agudo, Ruiz-Agudo, Sangwal, Schecher, Schofield, Singh, Stumm, Svensson, Tang, Tang, Tang, Taylor, Titiz-Sargut, Unwin, Unwin, Van Driessche, Van Rosmalen, Vanysek, Vavouraki, Wang, White, Wightman, Zhang   +95 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Workplace gender-based violence and associated factors among university women in Enugu, South-East Nigeria: an institutional-based cross-sectional study

BMC Women's Health, 2021
Background Exposure to workplace gender-based violence (GBV) can affect women's mental and physical health and work productivity in higher educational settings. Therefore, this study aimed to examine the prevalence of GBV (workplace incivility, bullying,
Olaoluwa Samson Agbaje, Chinenye Kalu Arua, Joshua Emeka Umeifekwem, Prince Christian Iheanachor Umoke, Chima Charles Igbokwe, Tochi Emmanuel Iwuagwu, Cylia Nkechi Iweama, Eyuche Lawretta Ozoemena, Edith N. Obande-Ogbuinya   +8 more
doaj   +1 more source

Kinetic, Spectroscopic, and X-Ray Crystallographic Evidence for the Cooperative Mechanism of the Hydration of Nitriles Catalyzed by a Tetranuclear Ruthenium-μ-oxo-μ-hydroxo Complex [PDF]

, 2008
The tetranuclear ruthenium-oxo-hydroxo-hydride complex {[(PCy3)(CO)RuH]4(μ4-O)(μ3-OH)(μ2-OH)} (1) was found to be a highly cooperative catalyst for the nitrile hydration reaction. The cooperative mechanism of the hydration of benzonitrile was established
Lindeman, Sergey V., Yi, Chae S., Zeczycki, Tonya N.   +2 more
core   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source